17 September, 2026 — In a landmark decision for public health policy, Members of the European Parliament (MEPs) have officially voted to adopt a sweeping report from the Parliament’s Public Health Committee regarding the management and prevention of cardiovascular diseases (CVDs). The vote represents a paradigm shift in how the European Union intends to tackle the growing burden of non-communicable diseases (NCDs), moving away from siloed, organ-specific interventions toward a more holistic, integrated model of care.
The report, which acts as a robust response to the European Commission’s "Safe Hearts Plan," underscores the inextricable link between cardiovascular and respiratory health. By formally recognizing that these conditions often coexist and share common risk factors, the European Parliament is paving the way for a more efficient, patient-centered approach to healthcare across all Member States.
Main Facts: The Shift Toward Integrated Care
The adopted report is not merely a policy document; it is a strategic roadmap intended to reshape European healthcare systems. At its core, the policy mandates a transition toward:
- Prevention-First Strategies: Shifting the focus from reactive treatment to proactive, lifestyle-based prevention.
- Early Detection Protocols: Implementing standardized screening measures that do not look at heart health in isolation.
- Cross-Disease Integration: Acknowledging that conditions like Chronic Obstructive Pulmonary Disease (COPD) and obstructive sleep apnoea are frequently comorbid with cardiovascular issues.
- Health Equity: Addressing the systemic inequalities that cause disparate health outcomes across different socioeconomic groups and regions within the EU.
For the European Respiratory Society (ERS), this vote is a long-awaited validation of its advocacy work. The Society has long argued that the heart and lungs function as a coupled system; when one fails, the other is almost invariably compromised. By including specific references to respiratory conditions in a cardiovascular-focused report, the Parliament has signaled that it understands the physiological reality of the human body, rather than the compartmentalized reality of hospital departments.
Chronology of the Initiative
The journey to this week’s vote has been a multi-year effort involving scientists, patient advocacy groups, and EU policymakers.
2024: Laying the Groundwork
The initiative began in earnest following a series of high-level consultations regarding the rising tide of NCDs. Data from the European Commission indicated that CVDs remained the leading cause of mortality in the EU, yet treatment pathways remained fragmented.
2025: The Launch of the "Safe Hearts Plan"
The European Commission unveiled the Safe Hearts Plan, a comprehensive framework aimed at reducing the burden of cardiovascular disease. While the plan was well-received, medical societies—including the ERS—identified a critical gap: the lack of focus on the respiratory comorbidities that often precede or exacerbate heart conditions.
Early 2026: Parliamentary Committee Deliberations
Throughout the first half of 2026, the European Parliament’s Public Health Committee held rigorous hearings. Stakeholders, including respiratory specialists and cardiovascular surgeons, provided testimony on the necessity of "dual-pathway" screenings. The committee integrated these findings into the final draft of the report, ensuring that respiratory health was given equal weight in the strategy.
September 2026: The Plenary Vote
On 17 September 2026, the European Parliament met in plenary session to cast their votes. The report passed with a significant majority, signaling strong cross-party support for the integrated health model.
Supporting Data: Why Integration Matters
The urgency of this report is driven by sobering data regarding the European health landscape. Cardiovascular disease remains the primary cause of death in the EU, responsible for over 3.9 million deaths annually. However, the prevalence of respiratory diseases is rising in tandem with an aging population and environmental factors.
The Comorbidity Crisis
Clinical research cited during the parliamentary sessions highlighted that patients with COPD have a significantly higher risk of developing ischemic heart disease and heart failure. Conversely, heart failure patients frequently experience sleep-disordered breathing, such as obstructive sleep apnoea.
Current health models, which often involve separate screenings for heart and lung issues, result in:
- Delayed Diagnosis: Patients often present with symptoms of one condition while the underlying systemic issue remains undetected.
- Increased Healthcare Costs: Fragmented care leads to repeated testing, duplicative administrative processes, and late-stage hospitalizations.
- Reduced Quality of Life: Patients struggling with multiple chronic conditions are often treated by specialists who do not communicate, leading to conflicting medication regimens.
The ERS has provided evidence that integrating a simple respiratory function assessment (such as spirometry) into standard cardiovascular risk checks could improve risk stratification. By identifying respiratory impairment early, doctors can implement preventative measures that stave off more severe, life-threatening cardiovascular events.
Official Responses and Expert Commentary
The adoption of the report has drawn praise from across the medical community. Raquel Duarte, the ERS Director of Scientific Affairs to the EU, has been at the forefront of the advocacy efforts.
In her official statement following the vote, Duarte emphasized that the success of the Safe Hearts Plan will depend on the "last mile" of implementation:
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together. The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte further noted the importance of equity, stating: "We particularly welcome the strong focus on prevention, COPD, and on addressing the risk factors and inequalities that continue to shape cardiovascular health outcomes across Europe."
She concluded with a call to action, noting that the scientific community and civil society must now work hand-in-hand with Member States to translate these high-level policy goals into local clinical practice.
Implications: The Road Ahead
What does this vote mean for the average European citizen? The implications are wide-reaching, affecting everything from how general practitioners conduct check-ups to how EU funds are allocated for medical research.
1. Standardized Health Checks
The most immediate potential change is the evolution of the "standard health check." The ERS is actively pushing for the inclusion of respiratory health in routine screenings. If implemented across all Member States, this would mean that a person visiting their doctor for a blood pressure check might also undergo a quick assessment of their lung function.
2. EU Screening Week
The vote aligns with the broader goals of EU Screening Week, an initiative that urges policymakers to put respiratory health on the map. The Parliament’s endorsement gives this initiative political teeth, providing a mandate for regional health authorities to prioritize respiratory testing in high-risk populations.
3. Cross-Disciplinary Training
The report implies a need for a new generation of healthcare professionals. Medical schools and continuing education programs may see a shift toward "integrated care" curricula, where cardiologists and pulmonologists are trained to better understand the diagnostic overlap between their fields.
4. Addressing Socioeconomic Inequalities
The report explicitly calls for a reduction in health inequalities. This will likely trigger new EU-funded initiatives aimed at providing better diagnostic tools to underserved areas, recognizing that cardiovascular and respiratory conditions are often more prevalent in populations facing environmental pollution, poor housing, and limited access to healthcare.
5. Institutional Cooperation
The next phase, as noted by ERS leadership, is the translation of the Safe Hearts Plan into concrete legislative measures. This will require the European Commission to coordinate closely with national ministries of health. The success of this policy will be measured not by the number of reports published, but by the tangible reduction in morbidity and mortality rates across the continent over the next decade.
Conclusion
The 17 September vote is a triumph of evidence-based policy. By acknowledging the complex, interconnected nature of human health, the European Parliament has taken a bold step toward a more sustainable and effective healthcare future. While the path to full implementation across 27 Member States will be complex, the foundation has been laid. For millions of Europeans, this integrated approach could mean the difference between a late-stage diagnosis and a lifetime of managed health.
For more information on the ERS and the European Lung Foundation’s advocacy efforts regarding this and other respiratory health initiatives, please visit the official ERS advocacy portal.
